Currently, a phase 1 study of IDH1-mutant gliomas is ongoing for determining the maximum tolerated dose (MTD) of ASTX727, which consists of DAC and E7727 (cedazuridine), a novel CDA inhibitor (ClinicalTrials.gov NCT03922555). The gene discussed is IDH1; the disease is glioma.